Stefania Bellone, PhD
Stefania Bellone, PhD
Assoc Rsrch Scientist Ob/Gyn
Yale University School of Medicine
333 Cedar Street
New Haven,
CT
USA
06520
Papers:
241 - Poster Session A
Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo